logo_ProQR-150x150.png
ProQR to Present at Two Upcoming Conferences
April 03, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR to Present at Upcoming Investor Conference
March 05, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
February 06, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
logo_ProQR-150x150.png
ProQR to Present at EuroTIDES Conference
October 31, 2017 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...